Synaptogenix Inc (SNPX)

[InTheTrenches]

If results are positive, this also opens the door to other diseases that have been studied pre-clinically with Bryostatin:

Rhett's syndrome
Traumatic Brain Injury
Stroke
Nieman-Pick disease

With a successful phase 2b, I expect the news flow over the next year will be tremendous, not only in Alzheimer's, but in these other diseases as well.

With a successful phase 2b, money won't be an issue, with probably $100M raised at >$50/share within 2 weeks.

With a successful phase 2b, funds and institutions will be piling into NTRP at a rapid pace under $100/share. No fund or institution will want to be caught without NTRP in their portfolio.

With a successful phase 2, and trials starting up in multiple diseases, I can easily see NTRP market cap getting in the range of $1-3 Billion within 3 months.